Patient’s 10-year prostate cancer-specific mortality shown graphically, compared to a cut-point used to guide patient selection for active surveillance.

“The cell-cycle risk score threshold appropriately dichotomized patients into low- and high-risk groups for 10-year prostate-cancer mortality, and may enable more appropriate selection of patients for active surveillance.”

Lin DW, et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology 2018; 36(6): 310.e7-310.e13.

Learn More View Article

Safely manage patients conservatively.

“The [cell cycle progression] score provides significant pretreatment prognostic information that cannot be provided by clinical variables and is useful for determining which patients can be safely managed conservatively, avoiding radical treatment.”

Cuzick J, Stone S, Fisher G, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015; 113:382–9.

Learn More View Article

Strongest independent predictor of cancer death outcome.

“For conservatively managed patients, the [cell-cycle progression] score is the strongest independent predictor of cancer death outcome yet described and may prove valuable in managing clinically localised prostate cancer.”

Cuzick J, Berney DM, Fisher G, et al. Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in conservatively managed needle biopsy cohort. Br J Cancer 2012 Mar 13; 106(6):1095-9.

Learn More View Article

Prolaris added significantly to prediction of BCR in multivariate analysis, both in overall cohort and subset of men meeting NCCN low risk criteria.

“In a cohort of NCCN low-risk patients, the CCP score improved clinical risk stratification of patients at increased risk of BCR [biochemical recurrence], which suggests the CCP score could improve the assessment of candidacy for active surveillance and guide optimal treatment selection in these patients with otherwise similar clinical parameters.”

Tosoian JJ, Chappidi MR, Bishoff JT, et al. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. BJU Int 2017; 120:808-14.

Learn More View Article

Prolaris predictor of metastatic disease, with no difference in predictive performance between races or treatment groups.

“Contrary to expectation, this study provides no evidence that African American men have more aggressive disease than non-African American men after accounting for all available molecular and clinicopatholgic prognostic information.”

Canter DJ, et al. Comparison of the prognostic utility of the cell cycle progression score for predicting clinical outcomes in African American and Non-African American men with localized prostate cancer. Eur Urol 2019 March; 75(3):515-22.

Learn More Download Poster View Article

Identify men likely to benefit from radiation after BCR.

“Among patients treated by radical prostatectomy who develop [biochemical recurrence], [cell cycle progression] score may predict systemic disease and could be used to help guide subsequent therapeutic interventions.”

Koch MO, Cho JS, Kaimakliotis HZ, et al. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. Cancer Biomarkers 2016 Jun; 17:83–8.

Learn More View Article

Guiding appropriate clinical care.

“[…] the [cell cycle progression] score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.”

Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the CCP score generated from biopsy in men treated with prostatectomy. J Urol 2014 Aug; 192(2):409–14.

Learn More View Article

Predicting biochemical recurrence in men with prostate cancer.

“[…] the [cell-cycle progression] score significantly predicted outcome and provided greater prognostic information than was available with clinical parameters.”

Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013 Aug; 86(5):848-53.

Learn More View Article

More accurate risk stratification.

“The cell-cycle progression (CCP) score may improve accuracy of risk stratification for men with clinically localized prostate cancer, including those with low-risk disease.”

Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013 Apr 10; 31(11):1428-34.

Learn More View Article

Prognostic value demonstrated in two cohorts with prostate cancer.

“The results of this study provide strong evidence that the cell cycle progression (CCP) score is a robust prognostic marker, which […] could have an essential role in determining the appropriate treatment for patients with prostate cancer.”

Cuzick J, Swanson GP, Fisher G, et al. Transatlantic Prostate Group. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011 Mar; 12(3):245-55.

Learn More View Article